20440T

7/15

17） Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology 2021; 73:158—91. PMID: 32430997 18） Yu C, Wu S, Zhao J, Lu J, Zhao T, Wei Y, et al. Evaluation of efficacy, safety and treatment—related outcomes of percutaneous radiofrequency ablation versus partial hepatectomy for small primary liver cancer meeting the Milan criteria: A systematic review and meta—analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2020; 44: 718—32. PMID: 31959566 19） Lee SH, Jin YJ, Lee JW. Survival benefit of radiofrequency ablation for solitary（3—5cm）hepa-tocellular carcinoma: An analysis for nationwide cancer registry. Medicine（Baltimore）2017;96: e8486. PMID: 29095307 20） Cucchetti A, Mazzaferro V, Pinna AD, Sposito C, Golfieri R, Serra C, et al. Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma. Br J Surg 2017; 104: 1704—12. PMID: 28745399 21） Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, et al. Impact of resection and ablation for single hypovascular hepatocellular carcinoma≤2cm analysed with propensity score weighting. Liver Int 2018; 38: 484—93. PMID: 29266722 22） Shiba S, Shibuya K, Katoh H, Kaminuma T, Miyazaki M, Kakizaki S, et al. A comparison of car-bon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepa-tocellular carcinoma: a propensity score matching study. Radiat Oncol 2019; 14: 137. PMID:31375120CQ 1081